-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 20, Innovent's Ipilimumab biosimilar drug IBI310 and its PD-1 monoclonal antibody Sintilizumab were approved for use in nasopharyngeal cancer IND applications
Currently, according to the Insight database, Cinda has carried out 6 clinical trials of IBI310 combined with Sintilimab in China for hepatocellular carcinoma, cervical cancer, postoperative adjuvant melanoma, and dMMR/MSI-H advanced colorectal cancer
Development of clinical trials of Sintilimab combined with IBI310
From the Insight database (http://db.